CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings

Nu Skin Enterprises announced third-quarter earnings, but the supplied article is truncated after saying revenue was “within” an unspecified range. The notice says the corrected release updates the nine months ended September 2026 figures for the deferred-tax-asset valuation allowance and adjusted net income; it provides no values or earnings details.

Analysis

The correction is confined to tax-allowance and adjusted-net-income lines in the nine-month EPS reconciliation; the supplied release does not show the revised figures or quantify any change to GAAP results, guidance, or cash flow. That makes the signal primarily one of disclosure quality, not yet a fundamentals revision. Near term, any NUS price reaction should depend on the size and direction of the EPS adjustment and whether it changes the apparent gap between GAAP and adjusted performance. Over the next 1–3 months, verify the corrected table against the original release and filing, and assess whether the valuation-allowance change is noncash and jurisdiction-specific or signals a broader change in expected tax attributes. A material adjustment, repeated corrections, or weaker underlying operating metrics would raise credibility and multiple risk; a small reconciliation-only change with unchanged guidance would likely have limited lasting impact. No defensible directional trade follows from the information provided.

Key Decisions for Investors

• Do not initiate a directional NUS position on this notice alone; obtain the corrected reconciliation and compare each affected figure with the prior version before updating estimates.
• Check the related filing for the size and cause of the deferred-tax-asset valuation-allowance change, its GAAP EPS impact, and whether it affects cash taxes or only adjusted presentation.
• Reassess only if the correction materially changes EPS interpretation, prompts a guidance change, or is followed by further reporting-control issues; otherwise treat as a watch item rather than a catalyst.